# Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

> **NCT01911325** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Buparlisib
- **DRUG:** Buparlisib matching placebo
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01911325
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Review of safety and preliminary efficacy data showed marginal anti-tumor activity.
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01911325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01911325, "Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01911325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*